News

SOTIO to Present Data Highlighting Progress Across ADC and Immunocytokine Programs at Upcoming Scientific Conferences

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new preclinical and translational data from multiple investigational programs at two scientific conferences in November – the World ADC Conference in San Diego, California, and PEGS Europe, in Lisbon, Portugal.

SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments

• SOT109 (targeting cadherin-17) exhibits potent efficacy and a favorable safety profile in preclinical models of colorectal cancer; currently in IND-enabling stage with IND filing anticipated in 2026; 

• SOT106 (targeting LRRC15) exhibits robust preclinical efficacy in mesenchymal tumors, including broad subset of sarcomas.

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, this week presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. 

SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline. The presentations will take place at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL from April 25-30, 2025.

SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer

• SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target;

• SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026;

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). The data highlight SOT109's promising activity and tolerability profile across multiple disease models, reinforcing its potential to become a best-in-class therapeutic for the treatment of colorectal cancer and other gastrointestinal (GI) cancers. The findings were presented at the 15th World ADC London 2025, taking place from March 3 to 6 at Novotel London West, London, UK.

SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target

• SOT109 will leverage antibodies generated with Biocytogen’s proprietary RenMab^TM platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers;

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics. The license will be used to develop an innovative antibody drug conjugate (ADC) for a novel tumor target under the option and license agreement established between the companies. The antibody selected will support the development of SOT109, SOTIO’s new ADC candidate, for the treatment of colorectal cancer and other gastrointestinal (GI) cancers.